Researchers And Clinicians
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
The Board of Scientific Advisors includes internationally recognized scientists, clinicians and biotechnology researchers.
Pierre Triozzi, MD
Vernon Stevens, PhD
Nora Disis, MD
Milton Tam, PhD
Louis Wiener, MD
John Majnarich, PhD
Pierre Triozzi, MD
Dr. Triozzi is currently Professor, Solid Tumor Oncology and Hematologic Malignancies and Blood Disorders at the Cleveland Clinic Cancer Center. With over 27 years of pioneering research in solid tumor oncology, Dr. Triozzi is considered one of the leading experts in researching the effects of hCG in the cancer process. Dr. Triozzi has conducted numerous research studies on hCG as well as publishing vital scientific articles on the subject. His special area of interests include medical oncology, melanoma, hematology, experimental therapeutics and cancer vaccines.
Dr. Triozzi has served on a number of councils and committees including the International Society for Biologic Therapy of Cancer, the National Cancer Institute and the American Federation for Clinical Research. Dr. Triozzi received his Medical Certification at Ohio State University in 1980 and he completed his residency, internship and fellowship at Duke University Medical Center.
Vernon Stevens, PhD
Dr. Stevens has had a forty-three year career in the field of reproductive biology and is the inventor of predecessor formulations of CG201. He is leading expert in the fields of vaccine development and contraception and has authored over 170 scientific publications in the areas of reproductive biology, endocrinology and cancer.
Dr. Stevens is Professor Emeritus at Ohio State University where he has been a faculty member since 1963. He is a member of numerous professional societies, and was a scientific advisor to ImmunoTherapy Corporation. Vern received his Ph.D. from Ohio State University in 1962.
Nora Disis, MD
Dr. Disis is an Associate Professor of Medicine at the University of Washington and an Associate Member of the Fred Hutchinson Cancer Research Center. She received her M.D. from the University of Nebraska Medical School and completed a residency and chief residency in Internal Medicine at the University of Illinois in Chicago. Her fellowship in oncology was done at the UW and the Hutchinson Center.
Dr. Disis is an expert in breast and ovarian cancer immunology and translational research. She is one of the pioneering investigators who discovered that HER-2/neu is a tumor antigen. Her work has led to several clinical trials, which evaluate boosting immunity to HER-2/neu with cancer vaccines. She is a member of the AACR Immunology Task Force, Deputy Editor for Translational Oncology for the Journal of Clinical Oncology, and Chair of the NCI Clinical Oncology Study Section. She is also the Director of the UW General Clinical Research Center and the Director for the Center of Translational Medicine in Women’s Health at the UW. Her multifaceted research program within the Tumor Vaccine Group includes the discovery of new antigens for breast and ovarian cancer and the development of vaccine and cellular therapy targeting those antigens.
Milton Tam, PhD
Dr. Tam has a 30-year career in immunology and biotechnology product development. He began his career at the Fred Hutchinson Cancer Research Center in Seattle where he was a scientist working in one of the first U.S. monoclonal antibody programs. Dr. Tam joined Genetic Systems Corporation in 1981 as one of its key employees and played a pivotal role in the building of that company. He was responsible for leading the technical development of the MicroTrak test for Chlamydia, the first rapid test for that infection, and participated in development of one of the first rapid, simple tests for HIV.
Following Genetic Systems, Dr. Tam became the Technical Director for the Program for Appropriate Technology in Health (PATH). At PATH, he established and led a group responsible for development of rapid and simple diagnostic technologies for infectious diseases and blood viruses. Through these efforts, PATH’s tests for HIV-1/HIV-2, hepatitis B virus, and tuberculosis, blood viruses, malaria, and other infectious diseases were transferred to commercial companies in developed and developing countries. He recently retired from PATH and is currently an independent consultant. Dr Tam is a research scientist by training, receiving his PhD in microbiology and immunology from the University of Washington.
Louis Wiener, MD
Dr. Weiner is Chairman of Medical Oncology and Vice President of Translational Research at Fox Chase Cancer Center in Philadelphia, Pennsylvania. A medical oncologist trained in research, Dr. Weiner directed Fox Chase’s immunotherapy program and developed and directed the medical oncology fellowship program prior to becoming the department chairman. Dr. Weiner has a longstanding interest and expertise in antibody engineering and antibody-based cancer therapy. In 2002 he was named the G. Morris Dorrance Jr. Endowed Chair in Medical Science, and was appointed as Fox Chase’s first Vice President for Translational Research. Dr. Weiner received a B.A. with Honors in Biology from the University of Pennsylvania in 1973 and the M.D. from Mount Sinai School of Medicine in 1977.
John Majnarich, PhD
Dr. Majnarich is a biochemist, biomedical research investigator, and an experienced research management executive who has been actively working on the development of human and animal therapeutic products for more than thirty years. He is President and Scientific Director of BioResearch, Inc. in Redmond, WA.
He was founder and Director of Biomed, Inc., developing and managing Biomed into one of the world’s leading fish vaccine companies. John was also a Director of the Biological Division of Schick Laboratories in Seattle. John holds a Ph.D. in Biochemistry from the University of Washington and currently serves as Director for several Seattle-area biotechnology companies.
